Rodrigo Núñez-Cortés, Joaquín Calatayud, Sergio Calonge-Pascual, Lars Louis Andersen, Rúni Bláfoss, José Francisco López-Gil, Rubén López-Bueno
{"title":"握力与阿尔茨海默病的剂量-反应关联：一项涉及85,979名成年人的纵向研究","authors":"Rodrigo Núñez-Cortés, Joaquín Calatayud, Sergio Calonge-Pascual, Lars Louis Andersen, Rúni Bláfoss, José Francisco López-Gil, Rubén López-Bueno","doi":"10.1002/gps.70137","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To investigate the dose-response relationship between handgrip strength and incidence of Alzheimer's disease (AD) in middle-aged and older adults.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>Longitudinal study.</p>\n </section>\n \n <section>\n \n <h3> Patients and Methods</h3>\n \n <p>A longitudinal study was conducted in people over 50 years old in 27 European countries and Israel. Data were collected from waves 1, 2, 4, 5, 6, 7 and 8 of the Survey of Health, Ageing and Retirement in Europe (SHARE) between February 2004 and January 2021. Handgrip strength was measured with a hand dynamometer. AD was self-reported based on previous diagnosis. Dose-response associations were assessed by restricted cubic splines.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 85,979 (55.8% female) participants were followed for a median of 9.3 years. Over this time, 3324 (3.9%) developed AD. In the adjusted model, for participants < 65 years, those in the middle third of handgrip strength showed a lower risk of AD compared to the lower third (HR = 0.63, 95% CI: 0.47–0.84), as well as participants in the upper third (HR = 0.63, 95% CI: 0.47–0.85). The spline model determined that the minimum and optimal doses of handgrip strength for a significant reduction in the risk of AD for those aged < 65 years were 54 kg (HR = 0.99; 95% CI: 0.08–0.99) and 56 kg (HR = 0.27; 95% CI: 0.08–0.91), respectively. Among those aged ≥ 65 years, the minimum and optimal doses were 31 kg (HR = 0.69; 95% CI: 0.48–0.99) and 49 kg (HR = 0.57; 95% CI: 0.43–0.76), respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Higher levels of handgrip strength showed a lower risk of developing AD, among adults aged 50 years and over. However, the dose-response relationship is limited to specific ranges according to age group. We identified a range between 54 and 56 kg years and a range between 31 and 49 kg as suitable to prevent AD in adults aged 50–64 and ≥ 65 years, respectively. Routine assessment of hand grip strength can help healthcare professionals identify people at increased risk of AD. Strength-based interventions could provide a practical strategy to support cognitive health and reduce the risk of dementia in clinical practice.</p>\n </section>\n </div>","PeriodicalId":14060,"journal":{"name":"International Journal of Geriatric Psychiatry","volume":"40 8","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gps.70137","citationCount":"0","resultStr":"{\"title\":\"Dose-Response Association of Handgrip Strength With Alzheimer's Disease: A Longitudinal Study Involving 85,979 Adults\",\"authors\":\"Rodrigo Núñez-Cortés, Joaquín Calatayud, Sergio Calonge-Pascual, Lars Louis Andersen, Rúni Bláfoss, José Francisco López-Gil, Rubén López-Bueno\",\"doi\":\"10.1002/gps.70137\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To investigate the dose-response relationship between handgrip strength and incidence of Alzheimer's disease (AD) in middle-aged and older adults.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Design</h3>\\n \\n <p>Longitudinal study.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Patients and Methods</h3>\\n \\n <p>A longitudinal study was conducted in people over 50 years old in 27 European countries and Israel. Data were collected from waves 1, 2, 4, 5, 6, 7 and 8 of the Survey of Health, Ageing and Retirement in Europe (SHARE) between February 2004 and January 2021. Handgrip strength was measured with a hand dynamometer. AD was self-reported based on previous diagnosis. Dose-response associations were assessed by restricted cubic splines.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 85,979 (55.8% female) participants were followed for a median of 9.3 years. Over this time, 3324 (3.9%) developed AD. In the adjusted model, for participants < 65 years, those in the middle third of handgrip strength showed a lower risk of AD compared to the lower third (HR = 0.63, 95% CI: 0.47–0.84), as well as participants in the upper third (HR = 0.63, 95% CI: 0.47–0.85). The spline model determined that the minimum and optimal doses of handgrip strength for a significant reduction in the risk of AD for those aged < 65 years were 54 kg (HR = 0.99; 95% CI: 0.08–0.99) and 56 kg (HR = 0.27; 95% CI: 0.08–0.91), respectively. Among those aged ≥ 65 years, the minimum and optimal doses were 31 kg (HR = 0.69; 95% CI: 0.48–0.99) and 49 kg (HR = 0.57; 95% CI: 0.43–0.76), respectively.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Higher levels of handgrip strength showed a lower risk of developing AD, among adults aged 50 years and over. However, the dose-response relationship is limited to specific ranges according to age group. We identified a range between 54 and 56 kg years and a range between 31 and 49 kg as suitable to prevent AD in adults aged 50–64 and ≥ 65 years, respectively. Routine assessment of hand grip strength can help healthcare professionals identify people at increased risk of AD. Strength-based interventions could provide a practical strategy to support cognitive health and reduce the risk of dementia in clinical practice.</p>\\n </section>\\n </div>\",\"PeriodicalId\":14060,\"journal\":{\"name\":\"International Journal of Geriatric Psychiatry\",\"volume\":\"40 8\",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gps.70137\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Geriatric Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/gps.70137\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Geriatric Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/gps.70137","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的探讨握力与中老年人阿尔茨海默病（AD）发病率的量效关系。设计纵向研究。患者和方法一项纵向研究在27个欧洲国家和以色列的50岁以上人群中进行。数据收集自2004年2月至2021年1月期间欧洲健康、老龄化和退休调查（SHARE）的第1、2、4、5、6、7和8轮。用手测力仪测量握力。AD是基于先前诊断的自我报告。剂量-反应关联通过受限三次样条进行评估。结果共有85,979名参与者（女性55.8%）被随访，中位时间为9.3年。在此期间，3324例（3.9%）患AD。在调整后的模型中，对于参与者<；65岁时，握力在中间三分之一的人患AD的风险低于握力在中间三分之一的人（HR = 0.63, 95% CI: 0.47-0.84），握力在中间三分之一的人患AD的风险低于握力在中间三分之一的人（HR = 0.63, 95% CI: 0.47-0.85）。样条模型确定了可显著降低老年人AD风险的最小和最佳握力剂量。65岁54 kg (HR = 0.99；95% CI: 0.08-0.99)和56 kg (HR = 0.27；95% CI: 0.08-0.91)。在年龄≥65岁的人群中，最小和最佳剂量为31 kg (HR = 0.69；95% CI: 0.48-0.99)和49 kg (HR = 0.57；95% CI: 0.43-0.76)。结论在50岁及以上的成年人中，握力水平越高，患AD的风险越低。然而，剂量-反应关系根据年龄组限制在特定范围内。我们确定54 - 56 kg /年和31 - 49 kg /年的范围分别适用于50-64岁和≥65岁的成年人预防AD。对手部握力的常规评估可以帮助医疗保健专业人员识别AD风险增加的人群。在临床实践中，以力量为基础的干预措施可以提供一种实用的策略，以支持认知健康并降低痴呆症的风险。
Dose-Response Association of Handgrip Strength With Alzheimer's Disease: A Longitudinal Study Involving 85,979 Adults
Objective
To investigate the dose-response relationship between handgrip strength and incidence of Alzheimer's disease (AD) in middle-aged and older adults.
Design
Longitudinal study.
Patients and Methods
A longitudinal study was conducted in people over 50 years old in 27 European countries and Israel. Data were collected from waves 1, 2, 4, 5, 6, 7 and 8 of the Survey of Health, Ageing and Retirement in Europe (SHARE) between February 2004 and January 2021. Handgrip strength was measured with a hand dynamometer. AD was self-reported based on previous diagnosis. Dose-response associations were assessed by restricted cubic splines.
Results
A total of 85,979 (55.8% female) participants were followed for a median of 9.3 years. Over this time, 3324 (3.9%) developed AD. In the adjusted model, for participants < 65 years, those in the middle third of handgrip strength showed a lower risk of AD compared to the lower third (HR = 0.63, 95% CI: 0.47–0.84), as well as participants in the upper third (HR = 0.63, 95% CI: 0.47–0.85). The spline model determined that the minimum and optimal doses of handgrip strength for a significant reduction in the risk of AD for those aged < 65 years were 54 kg (HR = 0.99; 95% CI: 0.08–0.99) and 56 kg (HR = 0.27; 95% CI: 0.08–0.91), respectively. Among those aged ≥ 65 years, the minimum and optimal doses were 31 kg (HR = 0.69; 95% CI: 0.48–0.99) and 49 kg (HR = 0.57; 95% CI: 0.43–0.76), respectively.
Conclusion
Higher levels of handgrip strength showed a lower risk of developing AD, among adults aged 50 years and over. However, the dose-response relationship is limited to specific ranges according to age group. We identified a range between 54 and 56 kg years and a range between 31 and 49 kg as suitable to prevent AD in adults aged 50–64 and ≥ 65 years, respectively. Routine assessment of hand grip strength can help healthcare professionals identify people at increased risk of AD. Strength-based interventions could provide a practical strategy to support cognitive health and reduce the risk of dementia in clinical practice.
期刊介绍：
The rapidly increasing world population of aged people has led to a growing need to focus attention on the problems of mental disorder in late life. The aim of the Journal is to communicate the results of original research in the causes, treatment and care of all forms of mental disorder which affect the elderly. The Journal is of interest to psychiatrists, psychologists, social scientists, nurses and others engaged in therapeutic professions, together with general neurobiological researchers.
The Journal provides an international perspective on the important issue of geriatric psychiatry, and contributions are published from countries throughout the world. Topics covered include epidemiology of mental disorders in old age, clinical aetiological research, post-mortem pathological and neurochemical studies, treatment trials and evaluation of geriatric psychiatry services.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
